SAN DIEGO, June 3, 2015 /PRNewswire/ -- aTyr Pharma, Inc.
(NASDAQ: LIFE), a biotherapeutics company engaged in the discovery
and development of Physiocrine-based therapeutics to address rare
diseases, today announced the Company's participation at the
35th Annual William Blair Growth Stock Conference to be
held at the Four Seasons Hotel in Chicago, IL, June 9-11,
2015.
John Mendlein, aTyr's CEO and
Executive Chairman, is scheduled to make a presentation on the
Company at 9:20 a.m. CT on
Wednesday, June 10, 2015. The
presentation will be webcast live through the "Investors" section
of the aTyr Pharma website at www.atyrpharma.com. An archived audio
replay will be available for 30 days following the initial
presentation webcast.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and clinical development
of innovative medicines for patients suffering from severe rare
diseases using its knowledge of Physiocrine biology, a newly
discovered set of physiological modulators. The Company's lead
candidate, Resolaris™, is a first-in-class intravenous protein
therapeutic for the treatment of rare myopathies with an immune
component.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atyr-pharma-to-present-at-35th-annual-william-blair-growth-stock-conference-300093048.html
SOURCE aTyr Pharma, Inc.